Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
Annals of Oncology, 10/13/09

Joensuu H et al. – Alternating administration of docetaxel and gemcitabine might result in improved time-to-treatment failure (TTF) and fewer adverse events compared with single-agent docetaxel as treatment of advanced breast cancer. The alternating regimen was associated with a similar TTF as single-agent docetaxel but with fewer adverse effects during gemcitabine cycles.

Methods

Women diagnosed with advanced breast cancer randomly allocated to receive 3-weekly docetaxel (group D) or 3-weekly docetaxel alternating with 3-weekly gemcitabine (group D/G) until treatment failure as first-line chemotherapy
Primary end point was TTF

Results

237 subjects assigned to treatment (group D, 115; group D/G, 122)
Median TTF 5.6 and 6.2 months in groups D and D/G, respectively
No significant difference in time-to-disease progression, survival, and response rate
When adverse events evaluated for worst toxicity encountered during treatment, was little difference between the groups, but when assessed per cycle, alternating treatment associated with fewer severe (grade 3 or 4) adverse effects , and the difference was highly significant for cycles when gemcitabine was administered in group D/G

<< Previous
Economic hardship associated with managing chronic illness: a...

Next >>
New-Onset Breast Tenderness After Initiation of Estrogen Plus...